These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 22616149

  • 1. [Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].
    Shitrit D, Talker O, Metabichek A, Yaakovi I.
    Harefuah; 2012 Apr; 151(4):216-9, 254, 253. PubMed ID: 22616149
    [Abstract] [Full Text] [Related]

  • 2. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM, QUALITX Study Investigators.
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.
    Maselli DJ, Singh H, Diaz J, Peters JI.
    Ann Allergy Asthma Immunol; 2013 Jun; 110(6):457-61. PubMed ID: 23706716
    [Abstract] [Full Text] [Related]

  • 4. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up.
    Menzella F, Facciolongo N, Piro R, Formisano D, Roggeri A, Simonazzi A, Castagnetti C, Carbonelli C, Zucchi L.
    Ther Adv Respir Dis; 2012 Apr; 6(2):87-95. PubMed ID: 22323442
    [Abstract] [Full Text] [Related]

  • 5. Omalizumab in the treatment of asthma.
    Tan R, Corren J.
    Expert Rev Respir Med; 2011 Dec; 5(6):747-56. PubMed ID: 22082161
    [Abstract] [Full Text] [Related]

  • 6. A 26-week, randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of omalizumab on asthma control in patients with persistent allergic asthma.
    Bardelas J, Figliomeni M, Kianifard F, Meng X.
    J Asthma; 2012 Mar; 49(2):144-52. PubMed ID: 22277052
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma.
    Ohta K, Miyamoto T, Amagasaki T, Yamamoto M, 1304 Study Group.
    Respirology; 2009 Nov; 14(8):1156-65. PubMed ID: 19909462
    [Abstract] [Full Text] [Related]

  • 8. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
    Tzortzaki EG, Georgiou A, Kampas D, Lemessios M, Markatos M, Adamidi T, Samara K, Skoula G, Damianaki A, Schiza S, Tzanakis N, Siafakas NM.
    Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma.
    Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H.
    Allergy; 2004 Jul; 59(7):701-8. PubMed ID: 15180756
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
    Padullés Zamora N, Comas Sugrañes D, Méndez Cabaleiro N, Figueras Suriol A, Jodar Masanes R.
    Farm Hosp; 2013 Jul; 37(5):399-405. PubMed ID: 24128103
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM, Humbert M, Bousquet J, Boulet LP, Hedgecock S, Blogg M, Fox H, Surrey K.
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A 36-month study on the cost/utility of add-on omalizumab in persistent difficult-to-treat atopic asthma in Italy.
    Dal Negro RW, Tognella S, Pradelli L.
    J Asthma; 2012 Oct; 49(8):843-8. PubMed ID: 22954018
    [Abstract] [Full Text] [Related]

  • 17. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients.
    Siergiejko Z, Świebocka E, Smith N, Peckitt C, Leo J, Peachey G, Maykut R.
    Curr Med Res Opin; 2011 Nov; 27(11):2223-8. PubMed ID: 21933100
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.